Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.
Malignant mesothelioma cells have an epithelioid or sarcomatoid morphology, both of which may be present in the same tumor. The sarcomatoid phenotype is associated with worse prognosis and heterogeneity of mesothelioma cells may contribute to therapy resistance, which is often seen in mesothelioma....
Main Authors: | Adam Szulkin, Gustav Nilsonne, Filip Mundt, Agata M Wasik, Pega Souri, Anders Hjerpe, Katalin Dobra |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3688685?pdf=render |
Similar Items
-
Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure
by: Rundlöf Anna-Klara, et al.
Published: (2009-06-01) -
Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.
by: Filip Mundt, et al.
Published: (2013-01-01) -
Diagnostic and Prognostic Value of Soluble Syndecan-1 in Pleural Malignancies
by: Filip Mundt, et al.
Published: (2014-01-01) -
Microenvironment-dependent phenotypic changes in a SCID mouse model for malignant mesothelioma
by: Eva eDarai-Ramqvist, et al.
Published: (2013-08-01) -
Predicting Malignant Mesothelioma by Analyzing Serum N-ERC/Mesothelin, C-ERC/Mesothelin, Hyaluronan, Osteopontin, and Syndecan-1 Levels
by: Sertaç Arslan, et al.
Published: (2017-12-01)